Mayo Clinic Laboratories > Oncology > Liquid biopsy cancer testing

Liquid biopsy cancer testing

A simplified solution with rapid results

Personalizing cancer care requires detailed information on the distinct genetic traits of an individual’s tumor. In some instances, however, attaining that information through traditional biopsy is not possible. In these instances — such as when tissue is not available for molecular testing, tissue biopsy is not feasible for the patient, biopsy location is difficult, or answers are required quickly — liquid biopsy blood testing can be a viable alternative.

80

80 GENES PROFILED FOR ctDNA MUTATIONS

10

10 ctRNA TARGETS ANALYZED FOR FUSIONS

15

15 cancer types targeted

Liquid Biopsy test menu

Liquid biopsy Liquid biopsy

Innovations that improve lives

Noninvasive and highly sensitive, LiquidHALLMARK® uses next-generation sequencing to target both DNA and RNA circulating in the blood to better understand a patient’s cancer. With just one blood draw, this first-in-class offering equips physicians with individualized insights associated with 15 cancers, which enables tailored treatment.

Offered in collaboration with Lucence, the LiquidHALLMARK® assay complements our comprehensive somatic cancer testing menu. Unique to the market, LiquidHALLMARK® sequences circulating RNA and DNA.

Key testing

Advantages

  • Employs highly sensitive next-generation sequencing to analyze ctDNA and ctRNA for clinically relevant biomarkers across various cancers.
    • Combining ctDNA and ctRNA has shown to increase the yield of clinically actionable alterations by 15.6% over similar liquid biopsy options.1
  • Profiles ctDNA mutations in 80 genes, ctRNA fusions in 10 genes, and somatic variants.
  • Returns results in 8–12 days.
  • Uses AmpliMark™, a proprietary amplicon-based enrichment chemistry for sequencing, to enable highly confident variant detection with an ultra-low analytical limit of detection (LOD):
    • 0.1% for SNVs and indels
    • 0.5% for ctDNA fusions
    • 10 copies for ctRNA fusions
Article LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study
Article Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial
References
  1. Dawar R, Carney J, Orsini J, et al. Amplicon-based liquid biopsy prospectively detects more tissue-confirmed guideline-recommended biomarkers in lung cancer. J Thorac Oncol. 2023;18(11):S256. ISSN 1556-0864, https://doi.org/10.1016/j.jtho.2023.09.431
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.